The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia

Background. Endometrial cancer (EC) treatment outcomes need to be improved. Immunotargeted therapy lead to long-term and delayed effects compared to chemotherapy. Estimation of long-term efficacy and quality of life are crucial when we are talking about efficacy in whole.Aim. To evaluate the long-term clinical efficacy of lenvatinib plus pembrolizumab therapy in patients with EC.Materials and methods. The study included 43 patients with stages I-IV EC with mismatch repair-proficient tumors and treatment duration of more than 9 months. We evaluated median progression-free survival, objective response, duration of treatment depending on the line of therapy, prevalence and type of adverse events, and correction regimens. Results. Lenvatinib plus pembrolizumab treatment was safe and efficacious in recurrent EC. Median of progression-free survival (patients with response or stabilization more than 9 months) is 10.2 months (95 % confidence interval 9.1-13.0), median of follow up is 9.7 (1.4-33.8) months. There were no complete responses, partial response was in 12 (28 %) patients, disease stabilization was in 31 (72 %) patients. Regarding safety, the overall rate of any-grade adverse events was 56.3 %. The most common treatment-related adverse events were fatigue (32.6 %), hypertension (23.3 %), and hypothyroidism (18.6 %). Dose reduction was performed in 22 (51.2 %) patients.Conclusion. The combination of lenvatinib plus pembrolizumab has long-term efficacy and manageable profile of safety. The presence of a significant pool of patients with durable response allows improving the survival rate of such patients in Russia.

Authors

Institutions

Publication Details

Journal
Tumors of female reproductive system
Published
2024-11-08
DOI
https://doi.org/10.17650/1994-4098-2024-20-3-69-77
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia

V. N. Orlova, N.K. Abduloeva, Л. В. Криволапова, Mavluda Ibragimova et al.
Tumors of female reproductive system
Endometrial and Cervical Cancer Treatments
article

The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia

V. N. Orlova, N.K. Abduloeva, Л. В. Криволапова, Mavluda Ibragimova, T. A. Makarkina, A. A. Abasova, Marina B. Bolieva, N. R. Abidova, S. V. Kuzmicheva, M. V. Volkonsky, E. B. Shakhnovich, I. A. Luev, O.A. Kuchevskaya, В. А. Чубенко, Х. С. Мусаева, А. В. Белоногов, R. S. Zhikhorev, А. А. Rumyantsev, V. A. Ekimov, Svetlana Soroka, Tigran Grigoryan, L. V. Strakh, Antonina N. Fedorova, L. V. Stepura, Е. В. Карабина, А. Г. Кедрова, А. Э. Протасова, A. A. Akopyan, A. A. Bobryshev, D. B. Sidorov, Maksim V. Zinkevich, V. M. Filippova, N. G. Graft, М. Э. Попова, M. Sheremet, Yu. V. Vasilyeva, Yu. I. Merzlikina, A. A. Lebedinets, А. Yu. Goryainova, E. V. Markizova, T. A. Zhelezkova, K. S. Maystrenko, L. B. Tatulova, E. V. Arsenyeva, D. Yu. Vovk, A. V. Zhizhina, T. A. Linchenko, A. A. Lisaeva, E. P. Krasnorutskaya, Yu. Yu. Pchelin, R. A. Ryanzhina, Igor Belogortsev, L. K. Semenov, F. Z. Aydaeva, O. N. Aymamedova, Olha Romanchuk, С. М. Алексеев, Vladimir Moiseyenko, E. V. Kogay
article en

Abstract

Background. Endometrial cancer (EC) treatment outcomes need to be improved. Immunotargeted therapy lead to long-term and delayed effects compared to chemotherapy. Estimation of long-term efficacy and quality of life are crucial when we are talking about efficacy in whole.Aim. To evaluate the long-term clinical efficacy of lenvatinib plus pembrolizumab therapy in patients with EC.Materials and methods. The study included 43 patients with stages I-IV EC with mismatch repair-proficient tumors and treatment duration of more than 9 months. We evaluated median progression-free survival, objective response, duration of treatment depending on the line of therapy, prevalence and type of adverse events, and correction regimens. Results. Lenvatinib plus pembrolizumab treatment was safe and efficacious in recurrent EC. Median of progression-free survival (patients with response or stabilization more than 9 months) is 10.2 months (95 % confidence interval 9.1-13.0), median of follow up is 9.7 (1.4-33.8) months. There were no complete responses, partial response was in 12 (28 %) patients, disease stabilization was in 31 (72 %) patients. Regarding safety, the overall rate of any-grade adverse events was 56.3 %. The most common treatment-related adverse events were fatigue (32.6 %), hypertension (23.3 %), and hypothyroidism (18.6 %). Dose reduction was performed in 22 (51.2 %) patients.Conclusion. The combination of lenvatinib plus pembrolizumab has long-term efficacy and manageable profile of safety. The presence of a significant pool of patients with durable response allows improving the survival rate of such patients in Russia.

Tumors of female reproductive systemVol. 20(3)
Kuban State Medical University (RU), St Petersburg University (RU), Central State Hospital (US), Federal Almazov North-West Medical Research Centre (RU), Moscow Clinical Scientific Center (RU), Ministry of Health of the Russian Federation (RU), City Hospital (GB), Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser (RU), City Clinical Hospital (RU), State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU), State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care (RU), North-Western State Medical University named after I.I. Mechnikov (RU), Russian Scientific Center of Surgery (RU), Ministry of Health (RW), Moscow City Oncology Hospital №62 (RU), Avaya (Bermuda) (BM), Federal Medical-Biological Agency (RU)
Openalex Percentile: Top 68%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.